Louis Moore Bacon's XBI Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 250,000 shares of State Street SPDR S&P Biotech ETF (XBI) worth $25.05 M, representing 0.34% of the portfolio. First purchased in 2016-Q4, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in XBI, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2022, adding 3.18 M shares. Largest reduction occurred in Q1 2023, reducing 2.9 M shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's State Street SPDR S&P Biotech ETF (XBI) Holding Value Over Time
Track share changes against reported price movement
Quarterly State Street SPDR S&P Biotech ETF (XBI) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2016 | +55,000 | New Buy | 55,000 | $59.18 |
| Q1 2017 | +245,000 | Add 445.45% | 300,000 | $69.34 |
| Q2 2017 | -300,000 | Sold Out | 0 | $0.00 |
| Q1 2020 | +225,000 | New Buy | 225,000 | $77.44 |
| Q2 2020 | -225,000 | Sold Out | 0 | $0.00 |
| Q4 2021 | +1.34 M | New Buy | 1.34 M | $111.96 |
| Q1 2022 | -1.25 M | Reduce 93.56% | 86,035 | $89.88 |
| Q2 2022 | -86,035 | Sold Out | 0 | $0.00 |
| Q4 2022 | +3.18 M | New Buy | 3.18 M | $83.00 |
| Q1 2023 | -2.9 M | Reduce 91.20% | 280,000 | $76.21 |
| Q2 2023 | -280,000 | Sold Out | 0 | $0.00 |
| Q3 2023 | +50,000 | New Buy | 50,000 | $73.02 |
| Q4 2023 | +1.74 M | Add 3480.00% | 1.79 M | $89.29 |
| Q1 2024 | -1.57 M | Reduce 87.71% | 220,000 | $94.89 |
| Q2 2024 | -15,000 | Reduce 6.82% | 205,000 | $92.71 |
| Q3 2024 | +47,500 | Add 23.17% | 252,500 | $98.80 |
| Q4 2024 | -252,500 | Sold Out | 0 | $0.00 |
| Q2 2025 | +150,000 | New Buy | 150,000 | $82.93 |
| Q3 2025 | +100,000 | Add 66.67% | 250,000 | $100.20 |
Louis Moore Bacon's State Street SPDR S&P Biotech ETF Investment FAQs
Louis Moore Bacon first purchased State Street SPDR S&P Biotech ETF (XBI) in Q4 2016, acquiring 55,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held State Street SPDR S&P Biotech ETF (XBI) for 19 quarters since Q4 2016.
Louis Moore Bacon's largest addition to State Street SPDR S&P Biotech ETF (XBI) was in Q4 2022, adding 3,182,662 shares worth $264.16 M.
According to the latest 13F filing for Q3 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 250,000 shares of State Street SPDR S&P Biotech ETF (XBI), valued at approximately $25.05 M.
As of the Q3 2025 filing, State Street SPDR S&P Biotech ETF (XBI) represents approximately 0.34% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in State Street SPDR S&P Biotech ETF (XBI) was 3,182,662 shares, as reported at the end of Q4 2022.